颅咽管瘤IFN-α囊内化学治疗的现状

doi:10.3877/cma.j.issn.2095-123X.2021.03.010

颅咽管瘤（CP）是一种儿童常见的颅脑良性肿瘤。囊内注射药物进行化学治疗是有效的治疗方式，包括放射性同位素、博来霉素以及干扰素（IFN）-α。IFN治疗后的CP患者，相较于传统的药物毒性产生的不良反应更轻微且多是可控的，但进行IFN治疗之前应进行渗漏检查。近十年研究证据表明，IFN-α治疗肿瘤控制程度好，不良反应小，是目前可靠的一种治疗选择，由于在国内缺乏足够的临床证据而未得到广泛的应用，但因其轻微的不良反应，同时能够保证较好的治疗效果，使得其成为替代传统囊内化学治疗药物最有潜力的选择。

关键词: 颅咽管瘤, 干扰素, 不良反应, 囊内化学治疗

Craniopharyngioma (CP) is a common benign brain tumor in children. Intracapsular injection of drugs for chemotherapy is an effective treatment, including radioisotopes, bleomycin and interferon (IFN)-α. Compared with traditional drugs, the adverse reactions of CP patients after IFN treatment are mild and mostly controllable, and leakage examination should be carried out before IFN treatment. According to the research evidence in the past decade, IFN-α is a reliable treatment option with good tumor control and less adverse reactions. It has not been widely used due to the lack of sufficient clinical evidence in China. However, because of its mild adverse reactions and good therapeutic effect, it has become the most potential alternative to traditional intracapsular chemotherapy.

Key words: Craniopharyngioma, Interferon, Adverse reaction, Intracapsular chemotherapy

表1 国内外关于干扰素-α治疗颅咽管瘤的相关文献

作者	例数	年龄[岁，范围（中位数）]	瘤体体积[cm³，范围（中位数）]		随访[月，范围（中位数）]	反应率[例（%）]
作者	例数	年龄[岁，范围（中位数）]	治疗前	治疗后	随访[月，范围（中位数）]	反应率[例（%）]
Cavalheiro S^[28]（2005）	10	1~18（10.0）	3.36~134.53（32.81）	0.03~6.24（1.94）	12~42（18）	9（100.0）
Ierardi DF^[30]（2007）	21	1~19（10.0）	3.36~134.53（31.17）	0.14~15.60（3.12）	6~48（25）	21（100.0）
Cavalheiro S^[29]（2010）	60	1~18（11.0）	3.30~134.50（27.70）	0.14~70.70（9.60）	4~48（44）	47（78.3）
Bartels U^[8]（2012）	6	4~18（10.8）	无	无	1~30（17）	4（80.0）
Dastoli PA^[31]（2011）	19	1~19（11.0）	3.36~134.53（33.50）	0.14~15.60（3.10）	17~45（36）	19（100.0）
Kilday JP^[32]（2017）	56	0~17（6.3）	无	无	1~12（32）	无
韩武^[33]（2019）	82	1~79（32.0）	6.63~220.75（20.92）	0~9.20（1.75）	3~30（18）	82（100.0）

表1 国内外关于干扰素-α治疗颅咽管瘤的相关文献

作者	例数	年龄[岁，范围（中位数）]	瘤体体积[cm³，范围（中位数）]		随访[月，范围（中位数）]	反应率[例（%）]
作者	例数	年龄[岁，范围（中位数）]	治疗前	治疗后	随访[月，范围（中位数）]	反应率[例（%）]
Cavalheiro S^[28]（2005）	10	1~18（10.0）	3.36~134.53（32.81）	0.03~6.24（1.94）	12~42（18）	9（100.0）
Ierardi DF^[30]（2007）	21	1~19（10.0）	3.36~134.53（31.17）	0.14~15.60（3.12）	6~48（25）	21（100.0）
Cavalheiro S^[29]（2010）	60	1~18（11.0）	3.30~134.50（27.70）	0.14~70.70（9.60）	4~48（44）	47（78.3）
Bartels U^[8]（2012）	6	4~18（10.8）	无	无	1~30（17）	4（80.0）
Dastoli PA^[31]（2011）	19	1~19（11.0）	3.36~134.53（33.50）	0.14~15.60（3.10）	17~45（36）	19（100.0）
Kilday JP^[32]（2017）	56	0~17（6.3）	无	无	1~12（32）	无
韩武^[33]（2019）	82	1~79（32.0）	6.63~220.75（20.92）	0~9.20（1.75）	3~30（18）	82（100.0）

[1]	Haupt R, Magnani C, Pavanello M, et al. Epidemiological aspects of craniopharyngioma[J]. J Pediatr Endocrinol Metab, 2006, 19 Suppl 1: 289-293.
[2]	Bunin GR, Surawicz TS, Witman PA, et al. The descriptive epidemiology of craniopharyngioma[J]. Neurosurg Focus, 1998, 3(6): e1.
[3]	Müller HL. Consequences of craniopharyngioma surgery in children[J]. J Clin Endocrinol Metab, 2011, 96(7): 1981-1991.
[4]	Buchfelder M, Schlaffer SM, Lin F, et al. Surgery for craniopharyngioma[J]. Pituitary, 2013, 16(1): 18-25.
[5]	Flitsch J, Müller HL, Burkhardt T. Surgical strategies in childhood craniopharyngioma[J]. Front Endocrinol (Lausanne), 2011, 2: 96.
[6]	Müller HL. More or less? Treatment strategies in childhood craniopharyngioma[J]. Childs Nerv Syst, 2006, 22(2): 156-157.
[7]	Müller HL, Gebhardt U, Pohl F, et al. Relapse pattern after complete resection and early progression after incomplete resection of childhood craniopharyngioma[J]. Klin Padiatr, 2006, 218(6): 315-320.
[8]	Bartels U, Laperriere N, Bouffet E, et al. Intracystic therapies for cystic craniopharyngioma in childhood[J]. Front Endocrinol (Lausanne), 2012, 3: 39.
[9]	Mrowczynski OD, Langan ST, Rizk EB. Craniopharyngiomas: a systematic review and evaluation of the current intratumoral treatment landscape[J]. Clin Neurol Neurosurg, 2018, 166: 124-130.
[10]	Leksell L, Liden K. A therapeutic trial with radioactive isotopes in cystic brain tumour[J]. Med Physiol Appl, 1952: 1-4.
[11]	Derrey S, Blond S, Reyns N, et al. Management of cystic craniopharyngiomas with stereotactic endocavitary irradiation using colloidal 186Re: a retrospective study of 48 consecutive patients[J]. Neurosurgery, 2008, 63(6): 1045-1052; discussion 1052-1053.
[12]	Julow J, Backlund EO, Lányi F, et al. Long-term results and late complications after intracavitary yttrium-90 colloid irradiation of recurrent cystic craniopharyngiomas[J]. Neurosurgery, 2007, 61(2): 288-295; discussion 295-296.
[13]	Musolino A, Munari C, Blond S, et al. Stereotaxic treatment of expanding cysts in craniopharyngiomas by endocavitary beta-irradiation (Re-186; Au-198; Y-90)[J]. Neurochirurgie, 1985, 31(3): 169-178.
[14]	Becker G, Kortmann RD, Skalej M, et al. The role of radiotherapy in the treatment of craniopharyngioma--indications, results, side effects[J]. Front Radiat Ther Oncol, 1999, 33: 100-113.
[15]	Merchant TE, Kiehna EN, Kun LE, et al. Phase II trial of conformal radiation therapy for pediatric patients with craniopharyngioma and correlation of surgical factors and radiation dosimetry with change in cognitive function[J]. J Neurosurg, 2006, 104(2 Suppl): 94-102.
[16]	Albright AL, Hadjipanayis CG, Lunsford LD, et al. Individualized treatment of pediatric craniopharyngiomas[J]. Childs Nerv Syst, 2005, 21(8-9): 649-654.
[17]	Zhang S, Fang Y, Cai BW, et al. Intracystic bleomycin for cystic craniopharyngiomas in children[J]. Cochrane Database Syst Rev, 2016, 7(7): CD008890.
[18]	Kubo O, Takakura K, Miki Y, et al. Intracystic therapy of bleomycin for craniopharyngioma--effect of bleomycin for cultured craniopharyngioma cells and intracystic concentration of bleomycin (author’s transl)[J]. No Shinkei Geka, 1974, 2(10): 683-688.
[19]	Takahashi H, Nakazawa S, Shimura T. Evaluation of postoperative intratumoral injection of bleomycin for craniopharyngioma in children[J]. J Neurosurg, 1985, 62(1): 120-127.
[20]	Hader WJ, Steinbok P, Hukin J, et al. Intratumoral therapy with bleomycin for cystic craniopharyngiomas in children[J]. Pediatr Neurosurg, 2000, 33(4): 211-218.
[21]	Alén JF, Boto GR, Lagares A, et al. Intratumoural bleomycin as a treatment for recurrent cystic craniopharyngioma. Case report and review of the literature[J]. Neurocirugia (Astur), 2002, 13(6): 479-485.
[22]	Cavalheiro S, Sparapani FV, Franco JO, et al. Use of bleomycin in intratumoral chemotherapy for cystic craniopharyngioma. Case report[J]. J Neurosurg, 1996, 84(1): 124-126.
[23]	Savas A, Erdem A, Tun K, et al. Fatal toxic effect of bleomycin on brain tissue after intracystic chemotherapy for a craniopharyngioma: case report[J]. Neurosurgery, 2000, 46(1): 213-216; discussion 216-217.
[24]	Haisa T, Ueki K, Yoshida S. Toxic effects of bleomycin on the hypothalamus following its administration into a cystic craniopharyngioma[J]. Br J Neurosurg, 1994, 8(6): 747-750.
[25]	Yeung JT, Pollack IF, Panigrahy A, et al. Pegylated interferon-α-2b for children with recurrent craniopharyngioma[J]. J Neurosurg Pediatr, 2012, 10(6): 498-503.
[26]	Jakacki RI, Cohen BH, Jamison C, et al. Phase II evaluation of interferon-alpha-2a for progressive or recurrent craniopharyngiomas [J]. J Neurosurg, 2000, 92(2): 255-260.
[27]	Gascon GG, International Consortium on Subacute Sclerosing Panencephalitis. Randomized treatment study of inosiplex versus combined inosiplex and intraventricular interferon-alpha in subacute sclerosing panencephalitis (SSPE): international multicenter study[J]. J Child Neurol, 2003, 18(12): 819-827.
[28]	Cavalheiro S, Dastoli PA, Silva NS, et al. Use of interferon alpha in intratumoral chemotherapy for cystic craniopharyngioma[J]. Childs Nerv Syst, 2005, 21(8-9): 719-724.
[29]	Cavalheiro S, Di Rocco C, Valenzuela S, et al. Craniopharyngiomas: intratumoral chemotherapy with interferon-alpha: a multicenter preliminary study with 60 cases[J]. Neurosurg Focus, 2010, 28(4): E12.
[30]	Ierardi DF, Fernandes MJ, Silva IR, et al. Apoptosis in alpha interferon (IFN-alpha) intratumoral chemotherapy for cystic craniopharyngiomas[J]. Childs Nerv Syst, 2007, 23(9): 1041-1046.
[31]	Dastoli PA, Nicácio JM, Silva NS, et al. Cystic craniopharyngioma: intratumoral chemotherapy with alpha interferon[J]. Arq Neuropsiquiatr, 2011, 69(1): 50-55.
[32]	Kilday JP, Caldarelli M, Massimi L, et al. Intracystic interferon-alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN[J]. Neuro Oncol, 2017, 19(10): 1398-1407.
[33]	韩武,于新,张剑宁,等.应用干扰素α-2b瘤内化疗治疗颅咽管瘤的临床观察[J].中国微侵袭神经外科杂志, 2019, 24(8): 360-363.
[34]	Mohammed KEA, Mike KRA, Parkes J. Unexpected brain atrophy following administration of intratumoral interferon alpha-2b for cystic craniopharyngioma: a case report[J]. Int J Case Rep Images, 2013, 4(12): 719-722.
[35]	Sharma J, Bonfield CM, Singhal A, et al. Intracystic interferon-α treatment leads to neurotoxicity in craniopharyngioma: case report[J]. J Neurosurg Pediatr, 2015, 16(3): 301-304.
[36]	Tiedemann LM, Manley P, Smith ER, et al. Visual field loss in a case of recurrent cystic craniopharyngioma during concomitant treatment with pegylated interferon α-2b[J]. J Pediatr Hematol Oncol, 2016, 38(1): e26-e28.
[37]	Asmana Ningrum R. Human interferon alpha-2b: a therapeutic protein for cancer treatment[J]. Scientifica (Cairo), 2014, 2014: 970315.
[38]	Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities[J]. Oncologist, 2001, 6(1): 34-55.
[39]	Samuel CE. Antiviral actions of interferons[J]. Clin Microbiol Rev, 2001, 14(4): 778-809, table of contents.
[40]	Chawla-Sarkar M, Lindner DJ, Liu YF, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis[J]. Apoptosis, 2003, 8(3): 237-249.
[41]	Bazhanova ED, Teplyǐ DL. Role of alpha-interferon in regulation of apoptosis in cells of the hypothalamo-hypophyseal-adrenocortical system of old mice in oxidative stress[J]. Morfologiia, 2004, 125(1): 23-26.
[42]	Bekisz J, Baron S, Balinsky C, et al. Antiproliferative properties of type I and type II interferon[J]. Pharmaceuticals (Basel), 2010, 3(4): 994-1015.
[43]	Sleijfer S, Bannink M, Van Gool AR, et al. Side effects of interferon-alpha therapy[J]. Pharm World Sci, 2005, 27(6): 423-431.
[44]	Meyers CA, Obbens EA, Scheibel RS, et al. Neurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal disease[J]. Cancer, 1991, 68(1): 88-92.
[45]	Hara S, Kimura H, Hoshino Y, et al. Combination therapy with intraventricular interferon-alpha and ribavirin for subacute sclerosing panencephalitis and monitoring measles virus RNA by quantitative PCR assay[J]. Brain Dev, 2003, 25(5): 367-369.
[46]	Bailey S, Parkes J. Intracystic interferon therapy in childhood craniopharyngioma: who, when and how?[J]. Clin Endocrinol (Oxf), 2015, 82(1): 29-34.

[1]	王青青, 耿翠芝, 苏晓雨, 彭玉晓, 秦明祎, 刘风侠. 乳腺癌芳香化酶抑制剂相关肌肉骨骼不良反应的研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(04): 243-249.
[2]	陈滔, 罗洪, 周进军. 老年食管癌单纯放疗及同期放化疗患者急性不良反应影响因素分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(04): 405-407.
[3]	陈瑜, 尤良顺, 孟海涛, 杨敏. 嵌合抗原受体T细胞治疗多发性骨髓瘤新进展[J]. 中华移植杂志(电子版), 2023, 17(05): 313-320.
[4]	季媛, 魏巴金. NLRP3炎性小体在器官移植不良反应发病机制中的研究进展[J]. 中华移植杂志(电子版), 2023, 17(05): 308-312.
[5]	罗婷, 张实. 5种生物标志物对ARDS预后的预测分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 471-475.
[6]	陈静, 张春明, 周斌, 吴明明. 甲苯磺酸瑞马唑仑联合瑞芬太尼全身麻醉对胸腔镜肺叶切除患者术后应激反应及血清PAF、γ干扰素的影响[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 554-556.
[7]	刘一, 文旖旎, 吴映辉. 过敏性紫癜患儿外周血辅助性T细胞、调节性T细胞细胞因子与肾损害的相关性分析[J]. 中华肾病研究电子杂志, 2023, 12(05): 271-275.
[8]	姜里蛟, 张峰, 周玉萍. 多学科诊疗模式救治老年急性非静脉曲张性上消化道大出血患者的临床观察[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 520-524.
[9]	张政赢, 鞠阳, 刘晓宁. 二甲双胍对2型糖尿病患者大肠腺瘤术后复发的影响[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 485-488.
[10]	盛静, 梅勇, 夏佩, 王晓林. 乌苯美司联合伊立替康二线治疗晚期胃癌的临床研究[J]. 中华消化病与影像杂志(电子版), 2023, 13(05): 317-321.
[11]	徐洪宇, 何亚爽. 羟考酮与氢吗啡酮用于胃癌根治术后镇痛的疗效[J]. 中华消化病与影像杂志(电子版), 2023, 13(05): 312-316.
[12]	董骏, 吴芳芳. mFOLFOX6与FOLFOX4化疗方案治疗直肠癌的临床疗效及安全性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(04): 236-240.
[13]	于晓东, 李德华, 高山, 徐鑫. 理中汤加味联合美沙拉嗪治疗轻度活动期克罗恩病的临床观察[J]. 中华消化病与影像杂志(电子版), 2023, 13(04): 199-202.
[14]	王昊, 明倩文, 王斌, 卢太坤, 张海宁. 利奈唑胺致黑毛舌的临床诊断学特征[J]. 中华诊断学电子杂志, 2023, 11(04): 254-260.
[15]	廖安琪, 王玫, 廖远泉. 达格列净诱发糖尿病患者血尿发生的临床诊断特征[J]. 中华诊断学电子杂志, 2023, 11(03): 169-172.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Current status of intracystic chemotherapy with IFN-α for craniopharyngioma

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Current status of intracystic chemotherapy with IFN-α for craniopharyngioma